GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hinge Health HNGE · USD

Health Care · US listing · 🇺🇸 United States

Compare

122.19

+5.55%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$587.9m

FY2023FY2025

Net income

−$528.3m

FY2023FY2025

Free cash flow

$170.7m

FY2023FY2025

Shareholders' equity

$378.5m

FY2023FY2025

Income statement

Fiscal years

FY2025FY2024FY2023
Revenue$587.9m$390.4m$292.7m
Gross profit$469.3m$300.6m$194.2m
Research and development$368.1m$100.8m$110.1m
Operating income−$546.4m−$31.9m−$130.5m
Net income−$528.3m−$11.9m−$108.1m
Diluted earnings per share-6.25-0.15-1.39

Balance sheet

At each fiscal year end

FY2025FY2024FY2023
Total assets$744.8m$673.3m$622.5m
Cash and short-term investments$363.9m$466.6m$423.4m
Total liabilities$366.2m$256.6m$195.3m
Debt$4.2m——
Shareholders' equity$378.5m$416.7m$427.3m
Shares outstanding85m78m78m

Cash flow

Fiscal years

FY2025FY2024FY2023
Cash from operations$171.4m$49.0m−$63.9m
Capital spending−$708,000−$3.8m−$4.6m
Free cash flow$170.7m$45.2m−$68.5m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$212.8m$182.3m$170.7m$154.2m$139.1m$123.8m$117.3m$100.6m
Gross profit$183.9m$154.2m$144.2m$126.2m$97.8m$100.2m$96.1m$79.2m
Operating income$40.4m$32.1m$27.3m−$6.1m−$580.7m$13.1m$20.9m−$3.8m
Net income$43.7m$35.1m$32.1m−$1.8m−$575.7m$121.3m$27.1m$341,000
Diluted earnings per share0.530.430.38-0.02-6.811.440.350.00
Cash from operations$101.0m$43.0m$63.0m$82.0m$20.0m$4.0m$38.0m$28.0m
Capital spending−$1.0m——−$1.0m−$1.0m—−$1.0m—
Free cash flow$100.0m——$81.0m$19.0m—$37.0m—
Total assets$827.4m$728.8m$744.8m$769.8m$693.7m$712.5m$675.5m—
Cash and short-term investments$389.4m$317.3m$363.9m$480.0m$413.3m$470.7m$468.4m—
Debt$4.3m$4.2m$4.2m$4.2m$4.0m$3.9m$7.6m—
Shareholders' equity$344.3m$311.6m$378.5m$407.9m$373.7m$438.8m$416.7m—

Financial ratios

Data as of 24 Oct 2026

FY2025FY2024FY2023
Gross margin79.8%77.0%66.3%
Operating margin-92.0%-6.3%-44.6%
Net margin-89.9%-3.1%-36.9%
Return on equity-139.6%-2.9%-25.3%
Return on assets-70.9%-1.8%-17.4%
Free cash flow yield1.8%0.6%-0.7%
Revenue growth50.6%33.4%—
Earnings growth4326.9%-89.0%—
Current ratio1.47x2.34x2.88x
Debt to equity0.01x0.01x0.01x
Equity ratio50.8%61.9%68.6%
R&D as a share of sales62.6%25.8%37.6%
Buybacks as a share of market value-8.4%-0.0%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin78.7%———

Valuation history

At each fiscal year end

FY2025
Price to earnings-7.4
Price to sales6.7

Share price return

Finished calendar years

2025
Return28%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.